Biogen reported additional Phase 2 lupus results for litifilimab, describing improvements in skin lesions that strengthen momentum toward potentially pivotal readouts. The company said the therapy improved outcomes after 24 weeks, with 14.7% reaching skin lesion response at the timepoint described in the report. The update adds to litifilimab’s development case as Biogen advances the program across two forms of lupus with the goal of establishing a more durable benefit profile. For clinicians, skin response is a key clinical anchor endpoint in lupus skin disease trials. Market reaction is likely to hinge on whether the new data can translate into consistent efficacy across patient subsets and differentiate from established immunology options.